December 4, 2013 / 2:35 PM / 4 years ago

Denmark's Genmab expands biotech collaboration with Janssen

COPENHAGEN (Reuters) - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.

Genmab said it will receive an initial payment of $2 million and potentially will be entitled to milestone and license payments of as much as $174 million to $219 million for each of ten additional programmes.

Reporting by Teis Jensen; Editing by David Goodman

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below